Featured Press Releases

Eden Expands Access to Glutathione Injection Protocols via Independent Licensed Providers and Pharmacies

Eden Expands Access to Glutathione Injection Protocols via Independent Licensed Providers and Pharmacies

Lubrizol reveals a significant milestone for its innovative, patented Apisolex™ polymer excipient

Lubrizol reveals a significant milestone for its innovative, patented Apisolex™ polymer excipient

  • 11 Jun 2025

Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1...

Scientific article highlights Namodenoson as promising for advanced liver cancer and MASH

Scientific article highlights Namodenoson as promising for advanced liver cancer and MASH

Great Bay Bio launches its Intelligent Drug Development Ecosystem

Great Bay Bio launches its Intelligent Drug Development Ecosystem

A Korea University study identifies mitochondrial dysfunction as a key factor in cognitive and metabolic impairments, offering insights into potential treatments

A Korea University study identifies mitochondrial dysfunction as a key factor in cognitive and metabolic impairments, offering insights into potential treatments

ZEISS Unveils AI-Powered Research Data Platform in Collaboration with Boehringer Ingelheim to Advance the Future of Personalized Eye Care

ZEISS Unveils AI-Powered Research Data Platform in Collaboration with Boehringer Ingelheim to Advance the Future of Personalized Eye Care

Innovent Biologics announces U.S. FDA IND approval for Phase 3 MarsLight-11 study of IBI363 in squamous NSCLC

Innovent Biologics announces U.S. FDA IND approval for Phase 3 MarsLight-11 study of IBI363 in squamous NSCLC

  • Innovent Biologics
  • 25 Aug 2025
Theravance Biopharma completes enrollment in Phase 3 CYPRESS study of Ampreloxetine for neurogenic orthostatic hypotension

Theravance Biopharma completes enrollment in Phase 3 CYPRESS study of Ampreloxetine for neurogenic orthostatic hypotension

  • Theravance Biopharma, Inc.
  • 25 Aug 2025
VASTHERA Receives U.S. FDA Clearance to Begin Phase 1 Clinical Trial of Pulmonary Arterial Hypertension Drug Candidate, VTB-10

VASTHERA Receives U.S. FDA Clearance to Begin Phase 1 Clinical Trial of Pulmonary Arterial Hypertension Drug Candidate, VTB-10

  • VASTHERA Co., Ltd.
  • 20 Aug 2025
CollPlant Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

CollPlant Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

  • CollPlant
  • 20 Aug 2025
GoodRx has announced a collaboration with Novo Nordisk to offer expanded access to Ozempic® and Wegovy® for $499 per month

GoodRx has announced a collaboration with Novo Nordisk to offer expanded access to Ozempic® and Wegovy® for $499 per month

  • GoodRx
  • 19 Aug 2025
In Afghanistan, WHO and UNICEF will launch a polio vaccination campaign utilizing the PharmaJet® Tropis® ID delivery system

In Afghanistan, WHO and UNICEF will launch a polio vaccination campaign utilizing the PharmaJet® Tropis® ID delivery system

  • PharmaJet
  • 19 Aug 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
August   2025
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.